[12] Patent
[11] Patent No.:GC0009323  
[45] Date of Publishing the Grant of the Patent: 31/Dec /2018                56/2018  
Number of the Decision to Grant the Patent:2018/141337
Date of the Decision to Grant the Patent:11/Dec/2018

[21] Application No.:GC 2011-19614

[22] Filing Date:26/10/2011

[30] Priority:

[33] State [32] Priority date [31] Priority No.
US
8/11/2010
61/411.137

[72] Inventors:1- Sajan Joseph،2- Susanta Samajdar

[73] Owner: Eli Lilly and company, Lilly Corporate Center, City of Indianapolis, Indiana 46285, USA

[74] Agent: Saba & Co. T.M.P

  

 

  

[51]IPC:
Int. Cl.7: [C07D401/14;A61K31/4995;A61P35/00]

[56] Cited Documents:

-WO 2008/117050 Al (ASTRAZ ENECA AB [SE] ;ASTRAZENECA UK LTD [GB]; ALMEIDA LYNS IE [US] ; IOA) 2 October 2008
-WO 2005/009435 Al (PFIZER [US]; JOHNSON MICHAEL DAVID [US]; TENG MIN [US] ; ZHU JINJIANG [) 3 February 2005
 
Examiner: PH. Sultana K. AlOudah

[54] COMPOUNDS USEFUL FOR INHIBITING CHK1
[57] Abstract: The present invention provides an aminopyrazole compound, or a pharmaceutically acceptable salt thereof, that inhibits Chk1 and is useful in the treatment of cancer.
No. of claims: 14


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.